Iterion Therapeutics announced that two abstracts featuring its first-in-class TBL1 inhibitor, tegavivint, will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
Researchers at the Cancer Research Institute and the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, have uncovered a critical mechanism that enables gastric cancer to spread to ...
Fig. 1: Wnt ligand expression promotes liver metastasis of gastric cancer. Two gastric organoid lines, KTP and WKTP were established from mouse stomach epithelium. KTP organoids carry driver mutations ...
Morning Overview on MSN
Researchers find some cancer drugs work differently than their stated targets
As of spring 2026, a cancer drug that has spent years in clinical development as a Wnt/beta-catenin pathway blocker has been ...
Comparative transcriptomic analysis of early- and late-onset colorectal cancer across TCGA, GEO, and CPTAC. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal Cancers Symposium. This ...
HOUSTON, March 25, 2026 /PRNewswire/ -- Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to advancing the treatment of Wnt-driven cancers, today reported that the first ...
Gastric (stomach) cancer remains one of the most common and deadly cancers in East Asia, including Korea. Yet despite its high prevalence, it has received far less molecular attention than colorectal ...
Researchers are rethinking how we target bowel cancer growth pathways, using patient-derived organoids to identify whether ...
Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, ...
Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results